Results 31 to 40 of about 231,116 (154)

Neoadjuvant immunotherapy in primary and metastatic colorectal cancer [PDF]

, 2021
Background Colorectal cancer (CRC) is the second most common solid organ cancer. Traditional treatment is with surgery and chemotherapy. Immunotherapy has recently emerged as a neoadjuvant therapy that could change treatment strategy in both primary ...
Søreide, Kjetil, K Søreide, Kanani, Arezo, T Veen, A Kanani, Veen, Torhild   +5 more
core   +1 more source

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma Is Associated with Improved Survival After Hepatectomy: A Matched Analysis of the 2017 to 2022 National Cancer Database. [PDF]

Cancers (Basel)
Background: Effects of neoadjuvant immunotherapy (NIT) before liver resection are not well-described in hepatocellular carcinoma (HCC). Survival and R0 resection rates in HCC patients undergoing curative-intent resection with or without NIT were ...
Chiang L, Bodzin A, Lin D, Hanna N, Koeneman S, Dang H, Yeo CJ, Shubert C, Zheng R.   +8 more
europepmc   +2 more sources

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A., Jauch, Karl-Walter, van den Engel, N.K., Fox, B.A., Grützner, S., Hatz, R.A., Rüttinger, D., Fox, B. A., Jauch, K.-W., Winter, H., van den Engel, N. K., Schendel, D. J., Pohlac, H., Pohla, H., Schlemmer, M., Schendel, D.J.   +15 more
core   +1 more source

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer

, 2021
Background and Objectives: Facing neoadjuvant chemotherapy followed by surgery, neoadjuvant immunotherapy is an innovative concept in localized muscle-invasive bladder cancer. Herein, we performed a review of the available and ongoing evidence supporting
Evanguelos Xylinas, Arthur Peyrottes, Gianluigi Califano, Jean-Francois Hermieu, Idir Ouzaid   +4 more
core   +1 more source

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis [PDF]

, 2013
© Queen’s Printer and Controller of HMSO 2013Severe allergic rhinitis uncontrolled by conventional medication can substantially affect quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim of reducing
B Kaambwa, P Barton, Barton, P, J Dretzke, Kaambwa, B, A Huissoon, Novielli, N, C Meads, A Meadows, A Fry-Smith, Dretzke, J, Huissoon, A, N Novielli, Fry-Smith, A, Meads, C, Meadows, A   +15 more
core   +1 more source

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis

Frontiers in Immunology, 2023
ObjectiveThis systematic review and meta-analysis aimed to investigate the role of neoadjuvant immunochemotherapy with or without radiotherapy [NIC(R)T] compared to traditional neoadjuvant therapies, without immunotherapy [NC(R)T].Summary background ...
Hesong Wang, Chunyang Song, Xiaohan Zhao, Wenzhao Deng, Jing Dong, Wenbin Shen   +5 more
doaj   +1 more source

Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects. [PDF]

Front Immunol
Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. For resectable early-stage NSCLC, surgery and adjuvant chemotherapy remain the standard treatments, but ...
Yang K, Wang L, Wang Z, Lv P, Cai C, Zhao H, Sun W, Wang B.   +7 more
europepmc   +2 more sources

Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings. [PDF]

Locally advanced esophageal cancer (LAEC) poses a significant and persistent challenge in terms of effective treatment. Traditionally, the primary strategy for managing LAEC has involved concurrent neoadjuvant chemoradiation followed by surgery. However,
Won Jin Jeon, Chieh Yang, Park, Daniel, Daniel Park, Dani Ran Castillo, Yang, Chieh, Castillo, Dani, Jeon, Won   +7 more
core   +1 more source

DataSheet_1_Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.docx

, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Linping Gu (12566571), Yaxian Yao (10837734), Yuwen Qi (12315921), Jie Shen (31533), Zhiwei Chen (254191), Shun Lu (402894)   +5 more
core   +1 more source

DataSheet_1_Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.zip

, 2023
BackgroundImmunotherapy has been approved for the treatment of metastatic colorectal cancer. The efficacy and safety of neoadjuvant immunotherapy for the treatment of non-metastatic colorectal cancer remains unclear.
Xiao-Quan Yang (1551754), Guang-yue Zhao (14512766), Feng-jian Wang (14512769), Long Zhou (103944), Xin Liu (43569)   +4 more
core   +1 more source